Department of Thoracic Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Department of molecular and cellular medicine, Tokyo Medical University, Tokyo, Japan.
Sci Rep. 2023 Mar 24;13(1):4823. doi: 10.1038/s41598-023-32041-5.
Lymphovascular invasion (LVI) is a fundamental step toward the spread of cancer. Extracellular vesicles (EVs) promote cellular communication by shuttling cargo, such as microRNAs (miRNAs). However, whether EV-associated miRNAs serve as biomarkers for LVI remains unclear. This study aimed to identify EV-associated miRNAs related to LVI and validate the miRNA levels from patients with early-stage lung adenocarcinoma (LADC). Blood samples were collected from patients undergoing pulmonary resection for stage I LADC before surgery. The patients were classified into three groups according to the presence of LVI and postoperative recurrence. Serum-derived EVs in the derivation cohort were used for small RNA sequencing, while the selected LVI miRNA candidates were validated via real-time quantitative polymerase chain reaction using 44 patient and 16 healthy donor samples as the validation cohorts. Five miRNAs (miR-99b-3p, miR-26a-5p, miR-93-5p, miR-30d-5p, and miR-365b-3p) were assessed, and miR-30d-5p (p = 0.036) levels were significantly downregulated in the LVI-positive group. miR-30d-5p levels in healthy donors were lower than those in LADC patients. Patients with high miR-30d-5p levels had favorable survival compared to those with low miR-30d-5p levels. miR-30d-5p level in EVs may serve as a promising biomarker for detecting LVI in patients with early-stage LADC.
淋巴血管侵犯(LVI)是癌症扩散的基本步骤。细胞外囊泡(EVs)通过转运货物(如 microRNAs(miRNAs))来促进细胞间通讯。然而,EV 相关的 miRNAs 是否作为 LVI 的生物标志物尚不清楚。本研究旨在鉴定与 LVI 相关的 EV 相关 miRNAs,并验证早期肺腺癌(LADC)患者的 miRNA 水平。在手术前,采集接受肺切除术治疗 I 期 LADC 的患者的血液样本。根据 LVI 和术后复发的存在,将患者分为三组。在推导队列中使用血清衍生的 EV 进行小 RNA 测序,而通过实时定量聚合酶链反应使用 44 名患者和 16 名健康供体样本作为验证队列来验证选定的 LVI miRNA 候选物。评估了 5 个 miRNA(miR-99b-3p、miR-26a-5p、miR-93-5p、miR-30d-5p 和 miR-365b-3p),miR-30d-5p(p=0.036)水平在 LVI 阳性组中显著下调。健康供体中的 miR-30d-5p 水平低于 LADC 患者。miR-30d-5p 水平较高的患者的生存情况优于 miR-30d-5p 水平较低的患者。EV 中的 miR-30d-5p 水平可能作为检测早期 LADC 患者 LVI 的有前途的生物标志物。